ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 729

Clinically Relevant Serum Proteins in Patients with Early Diffuse Cutaneous Systemic Sclerosis

Guoshuai Cai1, Kelsey S. Flood2, Shervin Assassi3, Elana J. Bernstein4, Robyn T. Domsic5, Jessica K. Gordon6, Faye Hant7, Elena Schiopu8, Virginia D. Steen9, Tracy M. Frech10, Dinesh Khanna11, Ami A. Shah12, Victoria K. Shanmugam13, Flavia V. Castelino14 and Monique Hinchcliff15, 1Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, 2Internal Medicine, Northwestern Medicine, Chicago, IL, 3University of Texas McGovern Medical School, Houston, TX, 4Rheumatology, Columbia University, New York, NY, 5Rheumatology, University of Pittsburgh, Pittsburgh, PA, 6Rheumatology, Hospital for Special Surgery, New York, NY, 7Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 8Internal Medicine, University of Michigan Medical System, Ann Arbor, MI, 9Rheumatology, MedStar Georgetown University Hospital, Washington, DC, 10Division of Rheumatology, University of Utah, Salt Lake City, UT, 11Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, 12Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 13Rheumatology, The George Washington University, Washington, DC, 14Rheumatology, Harvard Medical School, Boston, MA, 15Rheumatology, Northwestern Medicine, Chicago, IL

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: C Reactive Protein, proteomics, skin fibrosis and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS), an 11 center US cohort study of early diffuse cutaneous systemic sclerosis (dcSSc) patients, was designed to study dcSSc pathogenesis and patient response to treatments. Modified Rodnan skin score (mRSS), used to quantify skin severity, correlates with mortality. The study purpose was to identify a serum signature associated with dcSSc and correlated with mRSS.

Methods: Baseline serum samples and clinical data were collected from PRESS subjects at enrollment and healthy matched controls. Subjects met SSc ACR criteria, had early dcSSc (defined as < 2 years duration since first non-Raynaud symptom attributed to SSc; swollen hands or sclerodactyly; PLUS 1 or more of the following: present anti-topoisomerase I or anti-RNA polymerase III serum autoantibodies; proximal skin involvement; tendon friction rubs). Samples were subjected to a custom Multi-Analyte Profiles (MAP) that uses multiplexed ELISA for serum protein quantification. Analytes with >40% missing values were excluded. The fold-change in protein expression between early dcSSc versus control samples was calculated. A t-test was used to test for statistical significance with correction for multiple hypothesis testing using the Benjamini-Hochberg method. mRSS was fitted to a linear model to assess for correlation with protein expression.

Results: Characteristics of dcSSc patients and controls were summarized (Table 1). Of 109 analytes, 28 analytes with missing values were excluded, leaving 81 analytes for analysis. 45 proteins were differentially expressed between early dcSSc patients and controls at baseline (q-value <0.05, Table 2). ANG-2, IGFBP-2, MIP-3 beta, TNFR2 and myoglobin had >2 fold-change in dcSSc patients vs. controls (Fig 1). 106 out of 112 (95%) dcSSc patients had baseline mRSS values. C-reactive protein correlated with mRSS (Fig 1).

Conclusion: We identified 45 proteins with variable expression between early dcSSc patients and healthy controls. Further, we identified that C-reactive protein expression correlates with mRSS severity, which has also been shown to be associated with lung disease progression. Future work includes developing a mRSS-predictive model by studying changes in protein expression in patients with longitudinal mRSS.


Disclosure: G. Cai, None; K. S. Flood, None; S. Assassi, Bayer Healthcare, 2,Biogen Idec, 2,Reata, 5,Boehringer Ingelheim, 5; E. J. Bernstein, None; R. T. Domsic, None; J. K. Gordon, Corbus Pharmaceuticals, 2,Cumberland Pharmaceuticals, 2,Bayer Pharmaceuticals, 2; F. Hant, None; E. Schiopu, None; V. D. Steen, None; T. M. Frech, None; D. Khanna, Actelion Pharmaceuticals Ltd, Bayer, Bristol-Myers Squibb, Covis, Cytori, EMD Serono, Genentech/Roche, Gilead, GSK, Sanofi-Aventis, 5,NIH K24AR063120, 2; A. A. Shah, None; V. K. Shanmugam, Multiple, 9; F. V. Castelino, None; M. Hinchcliff, None.

To cite this abstract in AMA style:

Cai G, Flood KS, Assassi S, Bernstein EJ, Domsic RT, Gordon JK, Hant F, Schiopu E, Steen VD, Frech TM, Khanna D, Shah AA, Shanmugam VK, Castelino FV, Hinchcliff M. Clinically Relevant Serum Proteins in Patients with Early Diffuse Cutaneous Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/clinically-relevant-serum-proteins-in-patients-with-early-diffuse-cutaneous-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinically-relevant-serum-proteins-in-patients-with-early-diffuse-cutaneous-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology